Jens J. Holst

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Medicine, Endocrinology, Pharmacology +15

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Anne Flint, Anne Raben, Arne Astrup et al. · Journal of Clinical Investigation · 1998 · 1.4K citations · Full text

Life Sciences, Nutritional Sciences, Physiology +17

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander, Sten Madsbad, Jan Lysgaard Madsen et al. · The Lancet · 2002 · 1.3K citations

Medicine, Endocrinology, Internal Medicine +16

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Michael A. Nauck, N. Kleine, C. �rskov et al. · Diabetologia · 1993 · 1.1K citations · Full text

Medicine, Endocrinology, Internal Medicine +15

Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition

Ruud S. Kootte, Evgeni Levin, Jarkko Salojärvi et al. · Cell Metabolism · 2017 · 1K citations · Full text

Medicine, Endocrinology, Nutritional Sciences +17